These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26971793)

  • 41. Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
    Wecksler AT; Hwang SH; Wettersten HI; Gilda JE; Patton A; Leon LJ; Carraway KL; Gomes AV; Baar K; Weiss RH; Hammock BD
    Anticancer Drugs; 2014 Apr; 25(4):433-46. PubMed ID: 24525589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
    Jakubowicz-Gil J; Bądziul D; Langner E; Wertel I; Zając A; Rzeski W
    Pharmacol Rep; 2017 Aug; 69(4):779-787. PubMed ID: 28587939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
    Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
    Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
    Zou Z; Yin Y; Lin J; Hsu LC; Brandon VL; Yang F; Jove R; Jandial R; Li G; Chen MY
    J Neurosurg; 2016 May; 124(5):1310-8. PubMed ID: 26544779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
    Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
    BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
    World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
    Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
    Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
    PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma.
    Wang X; Shen C; Liu Z; Peng F; Chen X; Yang G; Zhang D; Yin Z; Ma J; Zheng Z; Zhao B; Liu H; Wang L; Wu J; Han D; Wang K; Zhong C; Hou X; Zhao W; Shu M; Wang X; Zhao S
    Cell Death Dis; 2018 Oct; 9(10):1032. PubMed ID: 30302016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma.
    Zhong C; Shu M; Ye J; Wang X; Chen X; Liu Z; Zhao W; Zhao B; Zheng Z; Yin Z; Gao M; Zhao H; Wang K; Zhao S
    BMC Cancer; 2019 May; 19(1):441. PubMed ID: 31088402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
    Xu JX; Yang Y; Zhang X; Luan XP
    Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y; Shimizu S; Takehara T; Harada M
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
    Muche S; Kirschnick M; Schwarz M; Braeuning A
    Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
    Jiang J; Zhang L; Chen H; Lei Y; Zhang T; Wang Y; Jin P; Lan J; Zhou L; Huang Z; Li B; Liu Y; Gao W; Xie K; Zhou L; Nice EC; Peng Y; Cao Y; Wei Y; Wang K; Huang C
    Autophagy; 2020 Jan; 16(1):106-122. PubMed ID: 30909789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Eum KH; Ahn SK; Kang H; Lee M
    Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
    Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.